A comprehensive approach toward novel serum biomarkers for benign prostatic hyperplasia: the MPSA Consortium.

[1]  Adam S. Kibel,et al.  Integrative molecular concept modeling of prostate cancer progression , 2007 .

[2]  Joshua R. Ehrlich,et al.  A native antigen “reverse capture” microarray platform for autoantibody profiling of prostate cancer sera , 2007, PROTEOMICS - Clinical Applications.

[3]  M. Rubin,et al.  A preliminary study of JM-27: a serum marker that can specifically identify men with symptomatic benign prostatic hyperplasia. , 2007, Journal of Urology.

[4]  J. Levitt,et al.  Prostate-specific antigen and prostate-specific antigen derivatives as predictors of benign prostatic hyperplasia progression , 2007 .

[5]  C. Niehrs,et al.  Function and biological roles of the Dickkopf family of Wnt modulators , 2006, Oncogene.

[6]  Weiliang Qiu,et al.  Development of a “reverse capture” autoantibody microarray for studies of antigen‐autoantibody profiling , 2006, Proteomics.

[7]  M. Kattan,et al.  1352: Baseline Serum BPH-A Level Enhances the Accuracy of a Nomogram to Predict BPH Progression in Men Enrolled on the GSK Phase III Dutasteride Trials , 2006 .

[8]  M. Kattan,et al.  1363: Prediction of Prostate Volume Using Molecular forms of PSA in Men with BPH Enrolled on the GSK PHASE III Dutasteride Trials , 2006 .

[9]  K. McVary.  BPH: epidemiology and comorbidities. , 2006, The American journal of managed care.

[10]  Vladimir Makarov,et al.  Whole transcriptome amplification for gene expression profiling and development of molecular archives. , 2006, Neoplasia.

[11]  G. Gennarini,et al.  Cross-Talk between F3/Contactin and Notch at Axoglial Interface: A Role in Oligodendrocyte Development , 2006, Developmental Neuroscience.

[12]  Joshua R. Ehrlich,et al.  The 'reverse capture' autoantibody microarray:a native antigen-based platform for autoantibody profiling , 2006, Nature Protocols.

[13]  M. Kattan,et al.  Development of nomogram to predict acute urinary retention or surgical intervention, with or without dutasteride therapy, in men with benign prostatic hyperplasia. , 2006, Urology.

[14]  R. Getzenberg,et al.  Benign prostatic hyperplasia cell line viability and modulation of jm-27 by doxazosin and Ibuprofen. , 2005, The Journal of urology.

[15]  R. Roberts,et al.  A population based study of incidence and treatment of benign prostatic hyperplasia among residents of Olmsted County, Minnesota: 1987 to 1997. , 2005, The Journal of urology.

[16]  John T. Wei,et al.  Urologic diseases in America project: benign prostatic hyperplasia. , 2005, The Journal of urology.

[17]  P. Romagnani,et al.  CXCR3-binding chemokines: novel multifunctional therapeutic targets. , 2005, Current drug targets. Immune, endocrine and metabolic disorders.

[18]  S. Shariat,et al.  BPSA: A Novel Serum Marker for Benign Prostatic Hyperplasia. , 2005, Reviews in urology.

[19]  R. Ransohoff,et al.  Chemokine receptor CXCR3: an unexpected enigma. , 2005, Current topics in developmental biology.

[20]  C. Roehrborn,et al.  Efficacy and Safety of Long-Term Treatment with the Dual 5α-Reductase Inhibitor Dutasteride in Men with Symptomatic Benign Prostatic Hyperplasia , 2004 .

[21]  C. Chapple.  Pharmacological therapy of benign prostatic hyperplasia/lower urinary tract symptoms: an overview for the practising clinician , 2004, BJU international.

[22]  R. Dhir,et al.  Androgen regulation of JM-27 is associated with the diseased prostate. , 2004, Journal of andrology.

[23]  Stephen M Hewitt,et al.  Discovery of protein biomarkers for renal diseases. , 2004, Journal of the American Society of Nephrology : JASN.

[24]  S. Shariat,et al.  Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer. , 2004, Urology.

[25]  M. Kattan,et al.  Beyond prostate-specific antigen: new serologic biomarkers for improved diagnosis and management of prostate cancer. , 2004, Reviews in urology.

[26]  C. Roehrborn,et al.  The long-term effect of doxazosin, finasteride, and combination therapy on the clinical progression of benign prostatic hyperplasia. , 2003, The New England journal of medicine.

[27]  H. Okano,et al.  F3/Contactin Acts as a Functional Ligand for Notch during Oligodendrocyte Maturation , 2003, Cell.

[28]  G. Cunha,et al.  Mouse urogenital development: a practical approach. , 2003, Differentiation; research in biological diversity.

[29]  S. Narumiya,et al.  Citron kinase, a Rho-dependent kinase, induces di-phosphorylation of regulatory light chain of myosin II. , 2003, Molecular biology of the cell.

[30]  Leonard S Marks,et al.  Benign prostate-specific antigen (BPSA) in serum is increased in benign prostate disease. , 2003, Clinical chemistry.

[31]  A. Sciarra,et al.  Distribution of inflammation, pre-malignant lesions, incidental carcinoma in histologically confirmed benign prostatic hyperplasia: a retrospective analysis. , 2003, European urology.

[32]  J. Girault,et al.  F3/contactin, a neuronal cell adhesion molecule implicated in axogenesis and myelination , 2002, Biology of the cell.

[33]  C. Roehrborn,et al.  Storage (irritative) and voiding (obstructive) symptoms as predictors of benign prostatic hyperplasia progression and related outcomes. , 2002, European urology.

[34]  A. Partin,et al.  Free prostate-specific antigen in serum is becoming more complex. , 2002, Urology.

[35]  R. Dhir,et al.  Symptomatic and asymptomatic benign prostatic hyperplasia: Molecular differentiation by using microarrays , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[36]  D. DeMets,et al.  Considerations in the evaluation of surrogate endpoints in clinical trials. summary of a National Institutes of Health workshop. , 2001, Controlled clinical trials.

[37]  J. Schalken,et al.  Immune response in hormonally-induced prostatic hyperplasia in the dog. , 2001, Veterinary immunology and immunopathology.

[38]  J. Morote,et al.  Prediction of Prostate Volume Based on Total and Free Serum Prostate–Specific Antigen: Is It Reliable? , 2000, European Urology.

[39]  R. Wolfert,et al.  "BPSA," a specific molecular form of free prostate-specific antigen, is found predominantly in the transition zone of patients with nodular benign prostatic hyperplasia. , 2000, Urology.

[40]  R. Bruskewitz.  Management of Symptomatic BPH in the US: Who Is Treated and How? , 1999, European Urology.

[41]  Downey,et al.  Asymptomatic inflammation and/or infection in benign prostatic hyperplasia , 1999, BJU international.

[42]  F. Di Cunto,et al.  Citron Rho-interacting Kinase, a Novel Tissue-specific Ser/Thr Kinase Encompassing the Rho-Rac-binding Protein Citron* , 1998, The Journal of Biological Chemistry.

[43]  J. Anim,et al.  Characterisation of inflammatory cells in benign prostatic hyperplasia. , 1998, Acta histochemica.

[44]  C. Roehrborn,et al.  The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group. , 1998, The New England journal of medicine.

[45]  C. Roehrborn,et al.  The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia , 1998 .

[46]  P. Schellhammer,et al.  Serum levels of endothelial and neural cell adhesion molecules in prostate cancer , 1997, The Prostate.

[47]  M. Barry,et al.  Measuring disease-specific health status in men with benign prostatic hyperplasia. Measurement Committee of The American Urological Association. , 1995, Medical care.

[48]  P. Humphrey,et al.  Tenascin expression in prostatic hyperplasia, intraepithelial neoplasia, and carcinoma. , 1993, Human pathology.

[49]  M. Barry,et al.  The American Urological Association symptom index for benign prostatic hyperplasia. The Measurement Committee of the American Urological Association. , 1992, The Journal of urology.

[50]  U. Stenman,et al.  A complex between prostate-specific antigen and alpha 1-antichymotrypsin is the major form of prostate-specific antigen in serum of patients with prostatic cancer: assay of the complex improves clinical sensitivity for cancer. , 1991, Cancer research.

[51]  H. Lilja,et al.  Molecular cloning of human prostate specific antigen cDNA , 1987, FEBS letters.